Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It is all in the RNS no 1014R dated 4th March 2021 if you can make sense of it
Under the original co-high licensing agreement riverwood high growth fund received certain convertible loan note and warrants.i won't recite the precise details of what they did with them,but the last relaible information we had was the RNS of 4/5/21 stating they had reduced their holding from 3.102% to 2.73%, totalling 7m shares. they may well have reduced further since then as the deal fell through and it would be a reasonable assumption to suggest they would sell down further following its failure. it is ,however,merely an assumption and nothing more.as they were below 3% in may 21,we will have had no statements of any dealings below that level. in case you are not clear, co-high was the licensee,but the shares were held by riverwood. both co high and riverwood are in effect owned by atlantis.
Sorry I am not following the analysis re who is selling. I am sure it is me!
Are you saying Co-High hold over 9m shares that they are trying to sell? I am
not aware that they are on the share registrar:please enlighten us. Given the holding that you suggest would be disclosed on the register and any significant sells would be subject to disclosure.
I think the sells are PI’s who think if they make £200 profit on a 4% rise they are the next Warren Buffet!!
Some time ago, I read that Trinity Delta’s modelling for Futura’s shares put a value of 30-40p on a MED3000 patent extension to 2040. Today, after news of the actual extension, the shares inched forward just over one penny.
The good news seeds of consistent operational achievements are falling on a fairly barren investor ground. Rather than producing the high yields we had been led to expect, and rationally ought to expect, the seeds are currently producing very low, and even zero, yields in terms of pushing the share price up. We are left scratching our heads for answers.
Over the past few months, the good news seeds have had to contend with a determined seller. I thought it might have been Lombard, but now the China / SE Asia agreement with Co-High has been terminated, the seller might be the latter. Its 9.8 million shares would not be easy to get rid off when annual daily turnover in Futura shares is vastly lower.
Price action does have a momentum element to it, so the fact that there’s been so much selling, with the shares down over 20p from their peak on news of the Haleon deal, has probably made some would-be buyers cautious. Ditto, James Barder’s recent uber-conservative musings. Ditto, many investors are still unaware of the sales volumes underpinning the £1.7m revenue in H1, and therefore exactly how much each sales unit will likely contribute to profit. Added to all this, there’s no sight of a desperately needed ‘Lombard-light’ institutional investor or investors to counterbalance the selling / wait and see pressure surrounding the shares. Plus, the SETSqx trading platform for Futura’s shares, with many more price quotes, is containing the volatility of the old days, when with just market makers we could have expected a 20%-30% gap up on opening today, rather than today’s unchanged movement.
After so many false dawns - of good news seeds with low yielding results - I do think that, among the levers Futura’s exec team could consider [also] using is releasing overall monthly sales volumes for Eroxon. Airlines like Ryanair, EasyJet and Wizzair publish monthly passenger volumes; mining companies publish monthly production reports. The publication of monthly Eroxon sales volumes could be time bound, say for the next 3 years, until most geographies have sales volumes. We are realising that six months is way too long to be waiting to learn sales volumes for a novel product. Investors desperately need to know that Eroxon is SELLING, whatever negative reviewers might want people to believe.
The absence of regular actual sales volumes is creating an information vacuum that is contributing to fragile investor confidence, so that good news seeds are left yielding very little in terms of upward share price movement.
I saw and heard this aswell lse1111. Very positive news indeed. There is clearly many dots still being connected with positive news flows anticipated over the next 6 months. I am not a behavioural psychologist. Barder appeared particularly chipper in the Proactive interview given his somewhat languid demeanour.
I sent this email to Trinity researchers today;
I was previously a stockbroker, but now just a private investor. I read your excellent research on Futura Medical, of which I am an investor, and I was wondering if you had seen the recent James Barder interview, and whether this might change your DCF model. Specifically in your note, "On the cusp of MED3000 commercialisation Update | 10 November 2022", you write under Valuation and Financials:
....However, pending visibility on the US terms, and given limited disclosure of precise terms in Europe (which includes multiple revenue layers based on various accounting practices) for simplicity we assume Futura Medical receives payments from partners that are equivalent to a royalty rate of 20% on in-market sales.
However on James Barder on Proactive Futura Medical "on track for a profit in 2025 after strong first half" 2 weeks ago when talking about financials about four minutes in says that margins are around 50%.
I was wondering if you would be looking to update your model in light of this information.
There is high probability of Haleon take-over however, this will be entirely dependent upon US patent protection. Also, in play will be the overall scope of protection. IMO
I was hoping for a bit more of a rise this morning, on the back of this RNS.
Maybe it will be climb some more when America wakes up and starts trading?
Haleon could add this product to their many other and pay a large premium for the right. What nice patent they can own. Got to be worth close to £1.00 or more for them to take us out. Strong buy. Big upside potential.
Https://www.proactiveinvestors.co.uk/pdf/create_new/news/details/1028322
Yes granular detail on sales is important but it not the only thing that matters as we have new launches around the world, updates on Haleon’s plans for the US and a launch timetable for the world’s biggest market would be nice. The news this morning is terrific but just part of the overall puzzle which should put a floor on the share price if one follows logic but this is AIM. New traders will be buying this am no doubt along with some longer term holders seeing how cheap this is a 45p. A series of regular commercial updates would be good to allow some positive momentum to develop rather than this stop start pattern.
Sales figures are the only thing that matters from now on
Massively increases the value for the company
Dont under estimate the power of patents
Can be used on the packaging etc and its a massive marketing boost
Game changer for the co
Was the one missing link holding it back
Excellent news.futura have significant experience in patent applications, so im not surprised, but extremely good news to have this confirmed.
I would imagine a large chunk of marketing expenditure hinged on this news. We can start to make a louder noise now.
GLA.
BRILLIANT RNS... hopefully we will have a really good day here.
Yeah here too!
https://www.futuramedical.com/investor-centre/
I would suggest "buy"
Futura Medical PLC - European Patent Granted for MED3000 until 2040 #FUM https://www.voxmarkets.co.uk/rns/announcement/738b84d1-e596-4010-aacd-5b2db70562d6 #voxmarkets undefined
lots of issues, investors not happy it seems, i understand, but why on earth were these questions not put to the ceo & coo on the 19th sept instead of ******** on here? the floor was open to ask what we liked and jb and angela were there to answer!
I have posted here a lot more than had anticipated. So my story; Like all LTH,s the frustration is clear and understandable. I also bought in quite low and from the trial success on-wards have even ended averaging up. However, have kept this side of the waterline.
One thing to consider about the company is, that it is a totally different beast today. It is no longer an R&D only outfit and it has a valuable and proven product. (The PI,s 'patience clock' should have been reset form this moment)
I have been a critic of the BoD in the past and, like many others here, feel that there is much room for improvement, especially in the communications department.
The hub of frustration is that fundamentally, all the ducks remain lined up however, the SP is not showing respect. Two conclusions can be derived from this synopsis.
Something is wrong - time to sell up
It's far too early and the message is not getting through - stay invested.
Martinelwick - I agree, Coopers missed a trick with the messaging and branding (pricing(?)). I do feel that the US launch (and future launches) will have the learning curve applied.
- On Saturdays we are all football managers.
Just seen an advertisement for Cialis on tv.Makes the point it only works if “turned on”
I have commented before that there is a problem with managing expectations with Eroxon. I think many have the impression that it is some sort of aphrodisiac and then give a negative review when they don’t get a hard on.
Moreover it emerged that the longer you used Eroxon the better it worked.
Not only do we need a reset re presentation of our story but also the advertising message.
I should make it clear I am an investor in the true sense of the word having taken part in two placings,so I am beyond patience with the current situation.
ThanksTDH. it did indeed!
Italian
Fair summary.
Historically Viagra also evolved for ED via an route where its original tests were not for that!